Stem definition | Drug id | CAS RN |
---|---|---|
4302 | 596-51-0 |
Dose | Unit | Route |
---|---|---|
3 | mg | O |
0.30 | mg | P |
3 | mg | R |
44 | mcg | Inhal.powder |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 17 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.37 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 16.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.65 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 11, 1961 | FDA | SHIONOGI INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 425.27 | 14.75 | 297 | 14500 | 91245 | 46580020 |
Dyspnoea | 231.09 | 14.75 | 504 | 14293 | 515044 | 46156221 |
Wheezing | 203.66 | 14.75 | 154 | 14643 | 53232 | 46618033 |
Obstructive airways disorder | 201.56 | 14.75 | 94 | 14703 | 13318 | 46657947 |
Chronic obstructive pulmonary disease | 197.50 | 14.75 | 156 | 14641 | 57477 | 46613788 |
Cough | 197.40 | 14.75 | 299 | 14498 | 229950 | 46441315 |
Forced expiratory volume decreased | 187.99 | 14.75 | 68 | 14729 | 5036 | 46666229 |
Total lung capacity increased | 164.06 | 14.75 | 40 | 14757 | 734 | 46670531 |
Sputum discoloured | 125.19 | 14.75 | 67 | 14730 | 12711 | 46658554 |
Productive cough | 99.11 | 14.75 | 100 | 14697 | 50615 | 46620650 |
Sleep apnoea syndrome | 77.88 | 14.75 | 61 | 14736 | 22140 | 46649125 |
Respiration abnormal | 75.14 | 14.75 | 34 | 14763 | 4487 | 46666778 |
Glaucoma | 74.42 | 14.75 | 52 | 14745 | 15869 | 46655396 |
Blood pressure systolic increased | 64.11 | 14.75 | 61 | 14736 | 28726 | 46642539 |
Lower respiratory tract infection | 64.00 | 14.75 | 83 | 14714 | 55006 | 46616259 |
Breast cancer recurrent | 63.69 | 14.75 | 29 | 14768 | 3882 | 46667383 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 63.02 | 14.75 | 17 | 14780 | 472 | 46670793 |
Forced vital capacity decreased | 56.76 | 14.75 | 18 | 14779 | 889 | 46670376 |
Lung neoplasm malignant | 53.11 | 14.75 | 42 | 14755 | 15447 | 46655818 |
Frustration tolerance decreased | 52.70 | 14.75 | 28 | 14769 | 5229 | 46666036 |
Rheumatoid arthritis | 52.59 | 14.75 | 7 | 14790 | 240208 | 46431057 |
Nasal congestion | 52.03 | 14.75 | 70 | 14727 | 48043 | 46623222 |
Pneumonia | 51.17 | 14.75 | 245 | 14552 | 376075 | 46295190 |
Hyper IgE syndrome | 49.69 | 14.75 | 12 | 14785 | 211 | 46671054 |
Secretion discharge | 47.54 | 14.75 | 32 | 14765 | 9187 | 46662078 |
Product use in unapproved indication | 45.38 | 14.75 | 93 | 14704 | 90180 | 46581085 |
Bronchial neoplasm | 43.39 | 14.75 | 11 | 14786 | 238 | 46671027 |
Humidity intolerance | 43.22 | 14.75 | 12 | 14785 | 372 | 46670893 |
Peak expiratory flow rate decreased | 41.39 | 14.75 | 13 | 14784 | 622 | 46670643 |
Nasal polyps | 41.15 | 14.75 | 18 | 14779 | 2192 | 46669073 |
Lung diffusion test decreased | 41.13 | 14.75 | 13 | 14784 | 635 | 46670630 |
Restrictive pulmonary disease | 40.20 | 14.75 | 15 | 14782 | 1211 | 46670054 |
Bronchial haemorrhage | 39.84 | 14.75 | 11 | 14786 | 334 | 46670931 |
Blood immunoglobulin E increased | 38.15 | 14.75 | 16 | 14781 | 1757 | 46669508 |
Nasal turbinate hypertrophy | 37.47 | 14.75 | 11 | 14786 | 418 | 46670847 |
Dyspnoea exertional | 36.88 | 14.75 | 61 | 14736 | 50228 | 46621037 |
Respiratory failure | 36.71 | 14.75 | 88 | 14709 | 94728 | 46576537 |
Pulmonary thrombosis | 36.52 | 14.75 | 25 | 14772 | 7377 | 46663888 |
Bronchial disorder | 35.17 | 14.75 | 13 | 14784 | 1022 | 46670243 |
Pulmonary function test decreased | 34.53 | 14.75 | 19 | 14778 | 3801 | 46667464 |
Endometrial ablation | 32.17 | 14.75 | 11 | 14786 | 689 | 46670576 |
Tachycardia | 31.85 | 14.75 | 86 | 14711 | 99536 | 46571729 |
Choking | 31.51 | 14.75 | 24 | 14773 | 8352 | 46662913 |
Drug hypersensitivity | 30.36 | 14.75 | 20 | 14777 | 243805 | 46427460 |
Infective exacerbation of chronic obstructive airways disease | 30 | 14.75 | 12 | 14785 | 1168 | 46670097 |
Chest discomfort | 29.94 | 14.75 | 79 | 14718 | 90190 | 46581075 |
Pain | 29.89 | 14.75 | 67 | 14730 | 476881 | 46194384 |
Oxygen saturation decreased | 29.85 | 14.75 | 67 | 14730 | 69097 | 46602168 |
Alopecia | 28.65 | 14.75 | 8 | 14789 | 162406 | 46508859 |
Nasal inflammation | 28.41 | 14.75 | 9 | 14788 | 443 | 46670822 |
Staphylococcal scalded skin syndrome | 27.63 | 14.75 | 7 | 14790 | 151 | 46671114 |
Staphylococcus test positive | 27.47 | 14.75 | 16 | 14781 | 3568 | 46667697 |
Asthmatic crisis | 27.39 | 14.75 | 12 | 14785 | 1466 | 46669799 |
Bronchiectasis | 27.18 | 14.75 | 23 | 14774 | 9293 | 46661972 |
Urinary retention | 26.77 | 14.75 | 37 | 14760 | 26024 | 46645241 |
Arthralgia | 26.44 | 14.75 | 47 | 14750 | 364556 | 46306709 |
Brain injury | 26.22 | 14.75 | 19 | 14778 | 6131 | 46665134 |
Perfume sensitivity | 26.15 | 14.75 | 9 | 14788 | 575 | 46670690 |
Blood count abnormal | 25.69 | 14.75 | 30 | 14767 | 17848 | 46653417 |
Sleep disorder due to a general medical condition | 25.18 | 14.75 | 15 | 14782 | 3484 | 46667781 |
Atrioventricular dissociation | 25.18 | 14.75 | 7 | 14790 | 218 | 46671047 |
Stress cardiomyopathy | 24.33 | 14.75 | 20 | 14777 | 7764 | 46663501 |
Rhinitis allergic | 24.25 | 14.75 | 19 | 14778 | 6889 | 46664376 |
Anaphylactic reaction | 23.52 | 14.75 | 52 | 14745 | 53060 | 46618205 |
Increased bronchial secretion | 23.27 | 14.75 | 11 | 14786 | 1603 | 46669662 |
Hypoventilation | 22.96 | 14.75 | 15 | 14782 | 4095 | 46667170 |
Middle insomnia | 22.78 | 14.75 | 21 | 14776 | 9494 | 46661771 |
Rhonchi | 22.77 | 14.75 | 12 | 14785 | 2203 | 46669062 |
Depression | 22.46 | 14.75 | 110 | 14687 | 169994 | 46501271 |
Sarcoidosis | 22.14 | 14.75 | 16 | 14781 | 5143 | 46666122 |
Rhinitis | 22.01 | 14.75 | 19 | 14778 | 7887 | 46663378 |
Polycystic ovaries | 21.71 | 14.75 | 10 | 14787 | 1374 | 46669891 |
Nasopharyngitis | 21.35 | 14.75 | 101 | 14696 | 153897 | 46517368 |
Sneezing | 21.06 | 14.75 | 23 | 14774 | 12718 | 46658547 |
Pulmonary oedema | 20.38 | 14.75 | 48 | 14749 | 51057 | 46620208 |
Body temperature abnormal | 20.17 | 14.75 | 9 | 14788 | 1149 | 46670116 |
Acute pulmonary oedema | 20.04 | 14.75 | 18 | 14779 | 7873 | 46663392 |
Rash | 19.99 | 14.75 | 53 | 14744 | 356459 | 46314806 |
Pulmonary congestion | 19.88 | 14.75 | 24 | 14773 | 14775 | 46656490 |
Infusion related reaction | 19.78 | 14.75 | 4 | 14793 | 101204 | 46570061 |
Upper airway obstruction | 19.15 | 14.75 | 7 | 14790 | 533 | 46670732 |
Apnoea | 19.15 | 14.75 | 17 | 14780 | 7322 | 46663943 |
Paranoia | 19.05 | 14.75 | 20 | 14777 | 10577 | 46660688 |
Diarrhoea | 18.58 | 14.75 | 103 | 14694 | 559499 | 46111766 |
Nausea | 18.50 | 14.75 | 135 | 14662 | 687319 | 45983946 |
Breath sounds abnormal | 18.23 | 14.75 | 17 | 14780 | 7798 | 46663467 |
Dystonia | 18.05 | 14.75 | 20 | 14777 | 11237 | 46660028 |
Abdominal discomfort | 18.00 | 14.75 | 13 | 14784 | 151152 | 46520113 |
Respiratory acidosis | 17.57 | 14.75 | 15 | 14782 | 6133 | 46665132 |
Treatment failure | 17.53 | 14.75 | 4 | 14793 | 93083 | 46578182 |
Influenza | 17.40 | 14.75 | 65 | 14732 | 89205 | 46582060 |
Respiratory distress | 17.35 | 14.75 | 34 | 14763 | 31882 | 46639383 |
Laryngospasm | 17.32 | 14.75 | 11 | 14786 | 2862 | 46668403 |
Tachypnoea | 17.24 | 14.75 | 22 | 14775 | 14329 | 46656936 |
Rales | 17.00 | 14.75 | 18 | 14779 | 9613 | 46661652 |
Mite allergy | 16.97 | 14.75 | 6 | 14791 | 415 | 46670850 |
Arthritis | 16.51 | 14.75 | 58 | 14739 | 77258 | 46594007 |
Joint swelling | 16.47 | 14.75 | 17 | 14780 | 166056 | 46505209 |
Congestive cardiomyopathy | 16.45 | 14.75 | 14 | 14783 | 5699 | 46665566 |
Rhinorrhoea | 16.08 | 14.75 | 42 | 14755 | 47623 | 46623642 |
Eosinophilic pneumonia chronic | 15.98 | 14.75 | 4 | 14793 | 82 | 46671183 |
Throat irritation | 15.97 | 14.75 | 31 | 14766 | 28870 | 46642395 |
Respiratory disorder | 15.97 | 14.75 | 30 | 14767 | 27270 | 46643995 |
Heart sounds | 15.75 | 14.75 | 5 | 14792 | 248 | 46671017 |
Seasonal allergy | 15.32 | 14.75 | 20 | 14777 | 13314 | 46657951 |
Irregular breathing | 15.32 | 14.75 | 5 | 14792 | 271 | 46670994 |
Upper respiratory tract inflammation | 15.13 | 14.75 | 10 | 14787 | 2785 | 46668480 |
Mucosal infection | 14.97 | 14.75 | 4 | 14793 | 107 | 46671158 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic obstructive pulmonary disease | 293.99 | 14.23 | 201 | 12103 | 45925 | 29894249 |
Dyspnoea | 213.20 | 14.23 | 439 | 11865 | 332856 | 29607318 |
Asthma | 167.36 | 14.23 | 130 | 12174 | 36044 | 29904130 |
Cough | 141.62 | 14.23 | 213 | 12091 | 125429 | 29814745 |
Wheezing | 103.08 | 14.23 | 92 | 12212 | 30846 | 29909328 |
Productive cough | 95.70 | 14.23 | 87 | 12217 | 29866 | 29910308 |
Forced expiratory volume decreased | 74.23 | 14.23 | 33 | 12271 | 3217 | 29936957 |
Blood immunoglobulin E increased | 54.25 | 14.23 | 22 | 12282 | 1708 | 29938466 |
Chest discomfort | 53.74 | 14.23 | 79 | 12225 | 45401 | 29894773 |
Lymph node calcification | 52.42 | 14.23 | 13 | 12291 | 195 | 29939979 |
Emphysema | 50.52 | 14.23 | 37 | 12267 | 9365 | 29930809 |
Dyspnoea exertional | 48.44 | 14.23 | 66 | 12238 | 35364 | 29904810 |
Tachycardia | 47.54 | 14.23 | 98 | 12206 | 73641 | 29866533 |
Serotonin syndrome | 43.95 | 14.23 | 45 | 12259 | 17846 | 29922328 |
Dyspnoea at rest | 42.59 | 14.23 | 21 | 12283 | 2585 | 29937589 |
Bronchial disorder | 40.70 | 14.23 | 15 | 12289 | 899 | 29939275 |
Bronchospasm | 34.90 | 14.23 | 31 | 12273 | 10307 | 29929867 |
General physical health deterioration | 34.82 | 14.23 | 105 | 12199 | 99839 | 29840335 |
Obstructive airways disorder | 34.29 | 14.23 | 29 | 12275 | 9030 | 29931144 |
Haemoptysis | 31.08 | 14.23 | 50 | 12254 | 31028 | 29909146 |
Secretion discharge | 30.17 | 14.23 | 19 | 12285 | 3756 | 29936418 |
Bronchial obstruction | 27.46 | 14.23 | 13 | 12291 | 1463 | 29938711 |
Toxicity to various agents | 27.06 | 14.23 | 20 | 12284 | 177163 | 29763011 |
Physical deconditioning | 26.71 | 14.23 | 10 | 12294 | 626 | 29939548 |
Lung neoplasm malignant | 26.68 | 14.23 | 32 | 12272 | 15100 | 29925074 |
Saliva altered | 25.24 | 14.23 | 7 | 12297 | 165 | 29940009 |
Cardiorenal syndrome | 24.88 | 14.23 | 10 | 12294 | 758 | 29939416 |
Rhinitis perennial | 23.01 | 14.23 | 6 | 12298 | 111 | 29940063 |
Lung disorder | 22.86 | 14.23 | 44 | 12260 | 31425 | 29908749 |
Pneumonia | 22.74 | 14.23 | 223 | 12081 | 334083 | 29606091 |
Product use issue | 21.64 | 14.23 | 54 | 12250 | 45962 | 29894212 |
Forced vital capacity decreased | 21.43 | 14.23 | 9 | 12295 | 763 | 29939411 |
Respiratory tract infection | 21.35 | 14.23 | 29 | 12275 | 15477 | 29924697 |
Pseudomonal sepsis | 21.26 | 14.23 | 14 | 12290 | 2986 | 29937188 |
Choking | 21.15 | 14.23 | 17 | 12287 | 4929 | 29935245 |
Sputum discoloured | 20.55 | 14.23 | 19 | 12285 | 6649 | 29933525 |
Smoke sensitivity | 20.45 | 14.23 | 6 | 12298 | 174 | 29940000 |
Grunting | 20.32 | 14.23 | 7 | 12297 | 344 | 29939830 |
Appendicitis perforated | 19.68 | 14.23 | 11 | 12293 | 1747 | 29938427 |
Drug intolerance | 19.08 | 14.23 | 51 | 12253 | 45240 | 29894934 |
Arrhythmia | 18.94 | 14.23 | 42 | 12262 | 33127 | 29907047 |
Pneumothorax | 18.92 | 14.23 | 28 | 12276 | 16165 | 29924009 |
Haemoglobin decreased | 18.57 | 14.23 | 12 | 12292 | 114086 | 29826088 |
Sputum purulent | 18.57 | 14.23 | 7 | 12297 | 447 | 29939727 |
Micturition urgency | 18.54 | 14.23 | 15 | 12289 | 4392 | 29935782 |
Sleep disorder due to a general medical condition | 18.44 | 14.23 | 10 | 12294 | 1497 | 29938677 |
Drug abuse | 17.39 | 14.23 | 6 | 12298 | 82066 | 29858108 |
Anaesthetic complication neurological | 16.79 | 14.23 | 6 | 12298 | 329 | 29939845 |
Pulmonary function test decreased | 16.77 | 14.23 | 14 | 12290 | 4281 | 29935893 |
Feeling cold | 16.77 | 14.23 | 20 | 12284 | 9379 | 29930795 |
Nasal polyps | 16.46 | 14.23 | 9 | 12295 | 1370 | 29938804 |
Angina pectoris | 16.43 | 14.23 | 37 | 12267 | 29481 | 29910693 |
Pulmonary function test abnormal | 16.36 | 14.23 | 9 | 12295 | 1387 | 29938787 |
Respiratory rate increased | 15.95 | 14.23 | 19 | 12285 | 8896 | 29931278 |
Urinary retention | 15.86 | 14.23 | 39 | 12265 | 32878 | 29907296 |
Buttock injury | 15.83 | 14.23 | 4 | 12300 | 65 | 29940109 |
Sitting disability | 15.71 | 14.23 | 4 | 12300 | 67 | 29940107 |
Prolonged expiration | 15.41 | 14.23 | 5 | 12299 | 204 | 29939970 |
Cataract | 15.21 | 14.23 | 30 | 12274 | 21805 | 29918369 |
Pancytopenia | 15.17 | 14.23 | 8 | 12296 | 85044 | 29855130 |
Chronic respiratory failure | 14.68 | 14.23 | 8 | 12296 | 1210 | 29938964 |
Respiratory disorder | 14.64 | 14.23 | 26 | 12278 | 17468 | 29922706 |
Xanthelasma | 14.32 | 14.23 | 4 | 12300 | 97 | 29940077 |
Source | Code | Description |
---|---|---|
ATC | A03AB02 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Synthetic anticholinergics, quaternary ammonium compounds |
ATC | D11AA01 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Antihidrotics |
ATC | R03BB06 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Anticholinergics |
ATC | A03CA05 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics |
ATC | R03AL04 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL07 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL12 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
MeSH PA | D000759 | Adjuvants, Anesthesia |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
FDA MoA | N0000175370 | Cholinergic Antagonists |
FDA EPC | N0000175574 | Anticholinergic |
CHEBI has role | CHEBI:35523 | bronchodilator agents |
CHEBI has role | CHEBI:48876 | antimuskarinika |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Peptic ulcer | indication | 13200003 | DOID:750 |
Chronic obstructive lung disease | indication | 13645005 | DOID:3083 |
General anesthesia | indication | 50697003 | |
Excessive salivation | indication | 53827007 | |
Vagal Reflex Bradycardia | indication | ||
Irritable bowel syndrome | off-label use | 10743008 | DOID:9778 |
Diarrhea | off-label use | 62315008 | |
Brain damage | contraindication | 2470005 | |
Tachyarrhythmia | contraindication | 6285003 | |
Suicidal thoughts | contraindication | 6471006 | |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Alcoholism | contraindication | 7200002 | |
Hyperammonemia | contraindication | 9360008 | |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Atony of colon | contraindication | 29479008 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Depressive disorder | contraindication | 35489007 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
Chronic heart failure | contraindication | 48447003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Peptic reflux disease | contraindication | 57643001 | |
Hepatic failure | contraindication | 59927004 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Poisoning by phenobarbital | contraindication | 64921004 | |
Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
Substance abuse | contraindication | 66214007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Spastic paralysis | contraindication | 78403003 | |
Disturbance of salivary secretion | contraindication | 78948009 | |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Autonomic dysreflexia | contraindication | 129618003 | |
Bleeding | contraindication | 131148009 | |
Myocardial dysfunction | contraindication | 233928007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Pyloric obstruction | contraindication | 244815007 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Dyspnea | contraindication | 267036007 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Drowsy | contraindication | 271782001 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Porphyria | contraindication | 418470004 |
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | July 23, 2023 | NEW COMBINULLTION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9.69 | SCIENTIFIC LITERATURE | CHEMBL | |||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 9.25 | SCIENTIFIC LITERATURE | IUPHAR | |||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.64 | SCIENTIFIC LITERATURE | CHEMBL | |||
Muscarinic acetylcholine receptor M4 | GPCR | ANTAGONIST | Ki | 9.06 | SCIENTIFIC LITERATURE | IUPHAR | |||
Muscarinic acetylcholine receptor M5 | GPCR | ANTAGONIST | Ki | 8.91 | SCIENTIFIC LITERATURE | IUPHAR |
ID | Source |
---|---|
4018421 | VUID |
N0000146747 | NUI |
D00540 | KEGG_DRUG |
51186-83-5 | SECONDARY_CAS_RN |
4018421 | VANDF |
4038210 | VANDF |
C0017970 | UMLSCUI |
CHEBI:94449 | CHEBI |
CHEMBL1201027 | ChEMBL_ID |
CHEMBL1201335 | ChEMBL_ID |
DB00986 | DRUGBANK_ID |
D006024 | MESH_DESCRIPTOR_UI |
11693 | PUBCHEM_CID |
7459 | IUPHAR_LIGAND_ID |
1038 | INN_ID |
V92SO9WP2I | UNII |
1546438 | RXNORM |
4794 | MMSL |
609 | MMSL |
d00992 | MMSL |
001737 | NDDF |
017641 | NDDF |
387122008 | SNOMEDCT_US |
769097000 | SNOMEDCT_US |
772943003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1250 | TABLET | 1 mg | ORAL | ANDA | 12 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1251 | TABLET | 2 mg | ORAL | ANDA | 12 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9584 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9585 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9586 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9587 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9679 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 24 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9680 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 24 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9681 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 24 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9682 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 24 sections |
Cuvposa | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0259-0501 | LIQUID | 1 mg | ORAL | NDA | 27 sections |
BEVESPI AEROSPHERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-4600 | AEROSOL, METERED | 9 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
BREZTRI | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0310-4616 | AEROSOL, METERED | 9 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4601 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4602 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4605 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4620 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8170 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6033 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6034 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6035 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6036 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6104 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6105 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6106 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Robinul | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6107 | INJECTION | 0.20 mg | INTRAMUSCULAR | NDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7097 | TABLET | 1.50 mg | ORAL | ANDA | 16 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3825 | INJECTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3827 | INJECTION | 0.40 mg | INTRAMUSCULAR | ANDA | 23 sections |
Glycopyrrolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3829 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 23 sections |